Mortality Risk Attributable to Atrial Fibrillation in Middle-Aged and Elderly People in the Japanese General Population

Ohsawa, Masaki; Okayama, Akira; Okamura, Tomonori; Itai, Kazuyoshi; Nakamura, Motoyuki; Tanno, Kozo; Kato, Karen; Yaegashi, Yasunori; Onoda, Toshiyuki; Sakata, Kiyomi; Ueshima, Hirotsugu

doi:10.1253/circj.71.814

Cited by 59 publications

(58 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19,25,26 The present study focused on PAF, which is different from previous clinical trials. In the present study, total mortality and cardiovascular morbidity rates were remarkably low compared with those in the previous studies, in which most or all patients had persistent AF.…”

Section: Cardiovascular Mortality and Morbidity In Pafmentioning

confidence: 99%

See 1 more Smart Citation

Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study

Ogawa¹,

Yamashita²,

Yamazaki³

et al. 2009

Circ J

182

120

View full text Add to dashboard Cite

Section: Cardiovascular Mortality and Morbidity In Pafmentioning

confidence: 99%

“…18,19 We herein present new data concerning rate and rhythm control strategies in patients with PAF.…”

mentioning

confidence: 99%

Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study

Ogawa¹,

Yamashita²,

Yamazaki³

et al. 2009

Circ J

182

120

View full text Add to dashboard Cite

“…However, since 2005, several reports have started to address this important issue in Japan. [4][5][6] The first of these studies was NIPPON DATA 80, 4 in which trial fibrillation (AF) is the most common arrhythmia among the developed countries, and its prevalence nearly doubles with each decade of life, increasing by as much as 25% on a lifetime basis. 1 As the population ages, the number of AF patients is predicted to increase.…”

Section: Mortality Rates Of Japanese Af Patientsmentioning

confidence: 99%

“…NIPPON DATA 80 4 reported that approximately 40% of the deaths were not of cardiovascular origin. In the J-TRACE study, 5 approximately 80% of the deaths were classified as "other" (not due to stroke, myocardial infarction, or major bleeding).…”

Section: Af Mortality and Morbidity In Japanmentioning

confidence: 99%

Recent Mortality and Morbidity Rates of Japanese Atrial Fibrillation Patients

Yamashita

2013

Circ J

View full text Add to dashboard Cite

“…4) However, antiarrhythmic drug therapy whose aim is the maintenance of sinus rhythm has prognostic limitations. 5) Recently, in order to correct arrhythmogenic structural remodeling of the atrial muscle, an etiological factor for AF, upstream therapy combining angiotensin-converting enzyme inhibitors (ACEI) and statins with antiarrhythmic agents, has drawn attention.…”

mentioning

confidence: 99%

Long-Term Efficacy of Upstream Therapy Using Angiotensin-Converting Enzyme Inhibitors and Statins in Combination With Antiarrhythmic Agents for the Treatment of Paroxysmal Atrial Fibrillation

et al. 2009

Self Cite

View full text Add to dashboard Cite

SummaryThe long-term efficacy of upstream therapy to prevent occurrence of paroxysmal atrial fibrillation (AF) in Japanese patients remains unclear. We retrospectively assessed the long-term efficacy of combination therapy with pravastatin (10 mg/day) and enalapril (5 mg/day) in addition to antiarrhythmic drugs (AAD) for maintaining sinus rhythm in patients with AF. This study included 319 patients (221 men, 98 women, mean age, 68 ± 10 years, mean follow-up period, 50 ± 34 months) who were divided into 4 groups: group I (n = 191) without combination therapy -namely pravastatin(-) and enalapril(-); group II (n = 81) with combination therapy -pravastatin (-) and enalapril (+) (n = 81); group III (n = 29) with combination therapy -pravastatin (+) and enalapril (-); and group IV (n = 18) with combination therapy -pravastatin (+) and enalapril (+). The percentages of patients free from conversion to permanent AF at 12, 36, 60, 90, and 120 months were as follows: group I 88, 83, 78, 75, and 73%, respectively; group II 96, 88, 79, 77, and 75%, respectively; group III 100, 97, 91, 91, and 86%, respectively; group IV 100, 100, 100, 94, and 94%, respectively. The actuarial rate free from conversion to permanent AF at 120 months was significantly higher in group IV than in group I (P < 0.05). The results suggest that in patients with paroxysmal AF, the addition of both pravastatin and enalapril to AAD was more effective for maintaining sinus rhythm in terms of an upstream therapy. (Int Heart J 2009; 50: 465-476)

show abstract

Mortality Risk Attributable to Atrial Fibrillation in Middle-Aged and Elderly People in the Japanese General Population

Abstract: AF affects stroke mortality, cardiovascular mortality and all-cause mortality in the Japanese general population. Careful attention should be paid to persons with AF in order to prevent future cardiovascular events.

Cited by 59 publications

References 22 publications

Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study

Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM Study

Recent Mortality and Morbidity Rates of Japanese Atrial Fibrillation Patients

Long-Term Efficacy of Upstream Therapy Using Angiotensin-Converting Enzyme Inhibitors and Statins in Combination With Antiarrhythmic Agents for the Treatment of Paroxysmal Atrial Fibrillation

Contact Info

Product

Resources

About